HomeTrialNCT07101094
🔬NCT07101094RECRUITING

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Study Summary

The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

Conditions
View on ClinicalTrials.gov ↗
Study Details
Enrollment300 participants
Primary Completion
Lead SponsorBristol-Myers Squibb
Data Retrieved2026-04-11 04:08:14.745834+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.